CorMatrix received the grant because of the potential of its ECM technology to improve cardiovascular disease treatment and outcomes.

CorMatrix said that the funds will be used for ongoing research into tissue regeneration, heart failure applications, drug-eluting ECM development, and to evaluate the CorMatrix ECM’s potential in reducing new onset post-operative atrial fibrillation.

President and chief operating officer Beecher Lewis said that they are pleased that the promise of their ECM Technology has been recognised and validated in this rigorous grant process and the funds will enhance the ability to continue developing regenerative cardiovascular technologies for patients, and to generate an ever more compelling body of clinical data supporting their use.